Manufacturing Services

Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.

For a bio/pharma industry in flux, contract services are playing a greater-and more diverse-role in drug development.

Packaging Coordinators, Inc. expands its services with acquisition of Penn Pharmaceutical Services.

Hovione will use Merrion's GIPET absorption-enhancing technology for solid-dosage drugs.

PharmSource special report shows demand for cytotoxic injectable drugs could tap existing CMO capacity.

With budgets growing, clients see CMOs' costs as less crucial.

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Thirteen companies are accepted for participation in the supply chain program.

CMOs may find opportunities in alternative expression services.

A changing biopharmaceutical industry is going beyond typically outsourced activities and is using CMOs for more challenging processes. Review the top 10 outsourcing trends.

PharmaCell enters an agreement purchase TiGenix therapy production facility.

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

Siegfried Schmitt, principal consultant at PAREXEL, discusses the state of drug manufacturing in India.

Data from BioPlan Associates’ 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.

Recipharm has invested EUR 32 million ($43 million) in its Wasserburg, Germany site to expand lyophilization capacity.

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

Are strategic partnerships in clinical research a model for CMC services?

Industry experts share their views on the outsourcing model and the current and future direction of contract chemical API manufacturing.

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

External manufacturing plays a crucial role in pharmaceutical companies’ supply strategy. The author examines market trends for the captive and merchant global market for active pharmaceutical ingredients and intermediates.

Contract service providers expand capabilities in API and finished product manufacturing to meet demand for high-potency drugs.

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Eisai and Biogen Idec pursue an innovative approach to capacity management.

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.

FDA's requirements for API manufacturers in regards to ICH Q7.

A UC Berkeley survey provides insight into biopharma's risk concerns and strategies.

Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends.

Will international biomanufacturing outsourcing become mainstream in this decade?

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.

Patheon will acquire softgel-specialist company Banner Pharmacaps, based in North Carolina in the US, for $255 million